Drug Trial Radar · NCT06662669
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Oct 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 30, 2024
Primary completion
Sep 30, 2027
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In Phase 1b study, six subjects will be enrolled in Arm A (YL-13027 + AG regimen) and Arm B (HY-0102 + AG regimen). The first 12 subjects will be evaluated for safety after one cycle. After safety assessment, subjects will start to enroll in Arm C (YL-13027 + HY-0102 + AG regimen). Each group is planned to include 12-20 subjects. According to the safety and efficacy results of 3 arms of subjects in phase Ib, 1-2 groups were selected for expansion, and a randomized controlled study will be conducted with the standard treatment AG (Arm 4)regimen chemotherapy.
Conditions
- Metastatic Pancreatic Cancer
Interventions
YL-13027Drug
YL-13027 is a small molecule inhibitor of the TGF-βRI target.
HY-0102Drug
HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
GemcitabineDrug
Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
Nab-paclitaxelDrug
Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months.
- Progression-free survivalTime frame: From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.